Главная Назад


Авторизация
Идентификатор пользователя / читателя
Пароль (для удалённых пользователей)
 

Вид поиска
Область поиска
в найденном
Найдено в других БД
Формат представления найденных документов:
библиографическое описаниекраткийполный
Отсортировать найденные документы по:
авторузаглавиюгоду изданиятипу документа
Поисковый запрос: (<.>S=ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ<.>)
Общее количество найденных документов : 167
Показаны документы с 1 по 20
 1-20    21-40   41-60   61-80   81-100   101-120      
1.
РЖ ВИНИТИ 76 (BI31) 95.02-04Т3.036

    Brunet, F.
    Interet de l'aztreonam dans le traitement des infections en reanimation [Text] / F. Brunet // Lett. infec. microbiol. clin. - 1992. - Hors.-ser.: Azoctam en 1992. - P50-52 . - ISSN 0296-9009
Перевод заглавия: Применение азтреонама в лечении инфекций при реанимации
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.07.39
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
АЗТРЕОНАМ
ДОЗИРОВАНИЕ
БОЛЬНЫЕ
РЕАНИМАЦИЯ
2.
РЖ ВИНИТИ 76 (BI31) 95.02-04Т3.149

    Rouveix, B.
    Tolerance de l'aztreonam [Text] / B. Rouveix // Lett. infec. microbiol. clin. - 1992. - Hors-ser.: Azoctam en 1992. - P69-71 . - ISSN 0296-9009
Перевод заглавия: Переносимость азтреонама
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.02
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
АЗТРЕОНАМ
ДОЗИРОВАНИЕ
КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ
ПЕРЕНОСИМОСТЬ
ПОБОЧНЫЕ ЭФФЕКТЫ
БОЛЬНЫЕ
3.
РЖ ВИНИТИ 76 (BI31) 95.02-04Т3.154

    Dellamonica, P.
    Aztroenam et infections osteo-articulaires [Text] / P. Dellamonica // Lett. Infec. Microbiol. Clin. - 1992. - Hors-ser.: Azoctam en 1992. - P57-58 . - ISSN 0296-9009
Перевод заглавия: Азтреонам и костно-суставные инфекции
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.31.99
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
КОСТНО-СУСТАВНЫЕ
АЗТРЕОНАМ
ДОЗИРОВАНИЕ
БОЛЬНЫЕ
4.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.46

    Meguro, Hidenori.
    Клиническая оценка применения нового орального препарата SY5555 в педиатрии [Text] / Hidenori Meguro, Ryochi Fujii, Utaru Terashima // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 41-48 . - ISSN 0368-2781
Аннотация: A new oral penem antibiotic, SY5555, was evaluated for its safety and efficacy in 35 children with various bacterial infections. SY5555 was effective in 100% of scarlet fever, pharyngotonsillitis, pneumonia, otitis media, bacterial diarrhea, urinary tract infections and skin and soft tissue infections. The etiologic bacteria were eradicated except Salmonella sp. Side effects were observed in 3,5% cases; one was diarrhea and Candida dermatitis, one was loose stool, and one was Candida dermatitis. From these data, SY5555 in thought to be a safe and effective antibiotic in the pediatric field. Regular dose of suspension preparation in 15 mg/kg/day in 3 divided dosages, and when needed the dose may be doubled
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.02.53
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
ПРОТИВОБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Fujii, Ryochi; Terashima, Utaru
5.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.47

   
    Фундаментальное и клиническое изучение SY 5555 в педиатрической практике [Text] / Takao Yokota [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 92-102 . - ISSN 0368-2781
Аннотация: We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDM). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85,1%. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76,7%. Side effects consisted of diarrhea in 12,5% (6 cases), loose stools in 4,2% (2 cases) and urticaria in 2,1% (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. The palatability of SY5555 dry syrup was very good; in was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful grug with a preferable safety profile in the treatment of pediatric patients with infectious diseases
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.02.53
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
АНТИБАКТЕРИАЛЬНАЯ АКТИВНОСТЬ
IN VITRO
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ

Доп.точки доступа:
Yokota, Takao; Akita, Hironobu; Sato, Yoshitake; Iwata, Satoshi; Sunakawa, Keisuke
6.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.49

   
    Клиническое изучение SY5555 в педиатрической практике [Text] / Kuniyoshi Kuno [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 129-132 . - ISSN 0368-2781
Аннотация: Clinical studies on SY5555 dry syrup, a new oral penem antibiotic, were carried out in the field of pediatrics. The following results were obtained. SY5555 was administered to 10 children with various bacterial infections (2 patients with acute tonsillitis, 2 with acute bronchitis, 1 with pharyngitis, 2 with scarlet fever, 1 with pertussis and 2 with urinary tract infections). The overall clinical efficacy rate was 90%. Side effects or abnormal laboratory test values were not observed except for loose stool in 1 and eosinophilia in 1
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.02.53
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY5555
ПРИМЕНЕНИЕ ВНУТРЬ
ПРОТИВОБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Kuno, Kuniyoshi; Ogawa, Akimasa; Hayakawa, Fumio; Miyajima, Yuji; Takahashi, Hideaki; Okumura, Akihisa; Kato, Toru; Itomi, Kazuya
7.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.239

   
    Бактериологическое, фармакокинетическое и клиническое изучение SY5555, применяемого в виде сиропа в педиатрической практике [Text] / Yoshikiyo Toyonaga [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 71-91 . - ISSN 0368-2781
Аннотация: The clinical responses were examined in a total of 73 cases including 4 acute pneumonia, 13 acute bronchitis, 11 tonsillitis, 3 pharyngitis, 12 scarlet fever, 2 pertussis, 6 urinary tract infection, 6 otitis media, 7 lymphadenitis, 2 staphylococcal scalded skin syndrome, 2 phlegmon, 4 impetigo and 1 purulent parotitis. The treatment was effective or better in 66 of 70 cases with an efficacy rate of 94.3% (3 undeterminable cases were excluded). Bacteriological effects were examined during the clinical course for detected or suspected pathogens found before administration of SY5555. The effects were determined in 50 cases including 7 cases of polymicrobacterial infections, 57 strains in total. Eight strains, however, persisted, hence the overall eradication rate was 86.0%. Because of the persistence of eight strains, the bacteriological efficacy rate was 84.0%. Except for mild watery stool which appeared in 1 case, no adverse reactions or abnormal laboratory test values were observed in any case
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.33.02
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY5555
ФАРМАКОКИНЕТИКА
АНТИБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Toyonaga, Yoshikiyo; Ishihara, Toshihide; Tezuka, Tohru; Nakamura, Horonori
8.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.254

   
    Изучение [клинической] эффективности и переносимости биапенема (L-627) при различных инфекциях у детей [Text] / Tsunekazu Haruta [et al.] // Jap. J. Antibiot. - 1994. - Vol. 47, N 12. - С. 1723-1727 . - ISSN 0368-2781
Аннотация: The efficacy and the safty of biapenem (L-627), a new carbapenem antibiotic, against infections in pediatrics were studied. The obtained results are summarized as follows. L-627 at dose levels of 5.4 mg/kg to 12.4 mg/kg (daily doses of 16.2 mg/kg to 37.2 mg/kg) was administered by intravenous drip infusion 3 times daily for 5 to 7 days to 2 cases of pneumonia, 3 cases of skin and solf-tissue infections and 1 case of urinary tract infection for a total of 6 cases. As results, all the cases showed good or better responses including 4 excellent and 2 good results. Bacteriological efficacies in all of the 3 eligible cases were assessed as "eradicated". As for the safety, a decrease in the WBC count and slight elevation of GOT and GPT were observed in 1 case as abnormal changes in the laboratory test results, only incidence of side effect observed was the eruption in 1 case. The results above indicate that L-627 is useful for the treatment of general infections in pediatrics
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.02
Рубрики: БИАПЕНЕМ (L-627)
ФАРМАКОКИНЕТИКА
ПЕРЕНОСИМОСТЬ
КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Haruta, Tsunekazu; Kuroki, Shigekazu; Ohkura, Kan-etsu; Nikami, Hiroyuki; Nishio, Toshikazu; Kabayashi, Yutaka
9.
РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.258

    Iwai, Naoichi.
    Лабораторное и клиническое изучение SY5555 в педиатрии [Text] / Naoichi Iwai, Haruhi Nakamura // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 103-128 . - ISSN 0368-2781
Аннотация: The clinical effect was evaluated in 29 cases including 1 scarlet fever, 12 acute purulent tonsillitis, 4 acute bronchitis, 6 acute pneumonia, 1 pertussis, 3 acute urinary tract infections and 2 impetigo. The results were excellent in 17 cases and good in 12 cases with an efficacy rate of 100.0%. As for the bacteriological effects on suspected pathogens including 4 strains of Staphylococcus aureus, 4 of Streptococcus pyogenes, 1 of Streptococcus pneumoniae, 1 of Moraxella (Branhamella) catarrhalis, 4 of Haemophilus influenzae, 2 of Escherichia coli and 1 of Bordetella pertussis, all strains were eradicated except 2 strains of H. influenzae that were judged as decreased or persisted and B. pertussis of which bacteriological examination was not performed after administration, thus the eradication rate was 87.5%. In addition, no bacterial alternation was observed in any case examined. Side effects observed included diarrhea and loose stool in 1 case each, either of which was mild. With respect to abnormal laboratory test results, only mild eosinophilia was observed in 2 cases, and 1 out of the 2 cases was later confirmed to have been normalized. The patients' compliance was generally good, with no patient complaining difficulties in intaking the drug, and all patients assessed the drug as easy to take. From these results, the drug seemed not only to have an excellent therapeutic effects on various infections of children but also to allow easy administration with a high level of safety
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.02
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
ЛЕЧЕНИЕ
НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY5555
ДОЗИРОВАНИЕ
КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ
БОЛЬНЫЕ ДЕТИ
АНТИБИОТИКИ

Доп.точки доступа:
Nakamura, Haruhi
10.
РЖ ВИНИТИ 34 (BI14) 95.10-04Б4.261

    Iwai, Naoichi.
    Лабораторное и клиническое изучение SY5555 в педиатрии [Text] / Naoichi Iwai, Haruhi Nakamura // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 103-128 . - ISSN 0368-2781
Аннотация: The clinical effect was evaluated in 29 cases including 1 scarlet fever, 12 acute purulent tonsillitis, 4 acute bronchitis, 6 acute pneumonia, 1 pertussis, 3 acute urinary tract infections and 2 impetigo. The results were excellent in 17 cases and good in 12 cases with an efficacy rate of 100.0%. As for the bacteriological effects on suspected pathogens including 4 strains of Staphylococcus aureus, 4 of Streptococcus pyogenes, 1 of Streptococcus pneumoniae, 1 of Moraxella (Branhamella) catarrhalis, 4 of Haemophilus influenzae, 2 of Escherichia coli and 1 of Bordetella pertussis, all strains were eradicated except 2 strains of H. influenzae that were judged as decreased or persisted and B. pertussis of which bacteriological examination was not performed after administration, thus the eradication rate was 87.5%. In addition, no bacterial alternation was observed in any case examined. Side effects observed included diarrhea and loose stool in 1 case each, either of which was mild. With respect to abnormal laboratory test results, only mild eosinophilia was observed in 2 cases, and 1 out of the 2 cases was later confirmed to have been normalized. The patients' compliance was generally good, with no patient complaining difficulties in intaking the drug, and all patients assessed the drug as easy to take. From these results, the drug seemed not only to have an excellent therapeutic effects on various infections of children but also to allow easy administration with a high level of safety
ГРНТИ  
34.27.29
ВИНИТИ 341.27.29.25.02
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
ЛЕЧЕНИЕ
НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY5555
ДОЗИРОВАНИЕ
КЛИНИЧЕСКАЯ ЭФФЕКТИВНОСТЬ
БОЛЬНЫЕ ДЕТИ
АНТИБИОТИКИ

Доп.точки доступа:
Nakamura, Haruhi
11.
РЖ ВИНИТИ 34 (BI14) 95.10-04Б4.262

   
    Фундаментальное и клиническое изучение SY 5555 в педиатрической практике [Text] / Takao Yokota [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 92-102 . - ISSN 0368-2781
Аннотация: We assessed the in vitro antimicrobial activity and the clinical efficacy and safety of SY5555 in the field of pediatrics. The results obtained are summarized below. In vitro antibacterial activities of SY5555 against 52 clinical isolates were compared with those of clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDM). Against Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes, SY5555 displayed antimicrobial activities superior or nearly equivalent to those of the reference agents used in the study. In cases of Gram-negative bacteria, the antimicrobial activity of SY5555 against Haemophilus influenzae was inferior to those of CPDX and CFDN. Against Klebsiella pneumoniae, the antimicrobial activity of SY5555 was less potent than that of CPDX. Forty-seven children with infectious diseases were treated with SY5555 dry syrup (powder dissolved just before use). The clinical results were excellent in 24 and good in 16, with an efficacy rate of 85,1%. Bacteriological screening identified 30 pathogenic organisms, and the eradication rate was 76,7%. Side effects consisted of diarrhea in 12,5% (6 cases), loose stools in 4,2% (2 cases) and urticaria in 2,1% (1 case) of the patients. The only abnormal laboratory test value observed was an increase in eosinophil count in one child. The palatability of SY5555 dry syrup was very good; in was very easily ingestible or easily ingestible by 32 of the 48 children. From the above results, SY5555 dry syrup appears to be a useful grug with a preferable safety profile in the treatment of pediatric patients with infectious diseases
ГРНТИ  
34.27.29
ВИНИТИ 341.27.29.25.02
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
АНТИБАКТЕРИАЛЬНАЯ АКТИВНОСТЬ
IN VITRO
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ

Доп.точки доступа:
Yokota, Takao; Akita, Hironobu; Sato, Yoshitake; Iwata, Satoshi; Sunakawa, Keisuke
12.
РЖ ВИНИТИ 34 (BI14) 95.10-04Б4.263

   
    Бактериологическое, фармакокинетическое и клиническое изучение SY5555, применяемого в виде сиропа в педиатрической практике [Text] / Yoshikiyo Toyonaga [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 71-91 . - ISSN 0368-2781
Аннотация: The clinical responses were examined in a total of 73 cases including 4 acute pneumonia, 13 acute bronchitis, 11 tonsillitis, 3 pharyngitis, 12 scarlet fever, 2 pertussis, 6 urinary tract infection, 6 otitis media, 7 lymphadenitis, 2 staphylococcal scalded skin syndrome, 2 phlegmon, 4 impetigo and 1 purulent parotitis. The treatment was effective or better in 66 of 70 cases with an efficacy rate of 94.3% (3 undeterminable cases were excluded). Bacteriological effects were examined during the clinical course for detected or suspected pathogens found before administration of SY5555. The effects were determined in 50 cases including 7 cases of polymicrobacterial infections, 57 strains in total. Eight strains, however, persisted, hence the overall eradication rate was 86.0%. Because of the persistence of eight strains, the bacteriological efficacy rate was 84.0%. Except for mild watery stool which appeared in 1 case, no adverse reactions or abnormal laboratory test values were observed in any case
ГРНТИ  
34.27.29
ВИНИТИ 341.27.29.25.02
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY5555
ФАРМАКОКИНЕТИКА
АНТИБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Toyonaga, Yoshikiyo; Ishihara, Toshihide; Tezuka, Tohru; Nakamura, Horonori
13.
РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.44

    Kino, Minoru.
    Клиническая оценка нового антибиотика [группа пенемов], SY5555, для приема внутрь у младенцев и детей [Text] / Minoru Kino, Hirohiko Higashino, Yohnosuke Kobayashi // Jap. J. Antibiot. - 1995. - Vol. 48, N 2. - С. 200-204 . - ISSN 0368-2781
Аннотация: A clinical study was performed on SY5555, a newly developed penem antibiotic, in children. SY5555 was given orally to 14 patients at 19'ЭКВИВ'29 mg/kg/day in 3 doses for 4 to 12 days. Clinical evaluations were made on the 14 patients including 4 with pharyngitis, 7 with tonsillitis, one with urinary tract infection, and 2 with impetigo. Overall clinical effects were excellent in 2, good in 12, with an efficacy rate of 100%. Causative organisms (Staphylococcus aureus and Streptococcus pyogenes) were all eradicated. As to adverse reactions, mild diarrhea was observed in 4 patients. These data suggest that SY5555 is a useful oral antibiotic for the treatment of bacterial infections in children. Библ. 5
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.02.53
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
ДОЗИРОВАНИЕ
АНТИБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
ЛЕЧЕНИЕ
БОЛЬНЫЕ ДЕТИ
МЛАДЕНЦЫ

Доп.точки доступа:
Higashino, Hirohiko; Kobayashi, Yohnosuke
14.
РЖ ВИНИТИ 34 (BI14) 95.11-04Б4.365

    Kino, Minoru.
    Клиническая оценка нового антибиотика [группа пенемов], SY5555, для приема внутрь у младенцев и детей [Text] / Minoru Kino, Hirohiko Higashino, Yohnosuke Kobayashi // Jap. J. Antibiot. - 1995. - Vol. 48, N 2. - С. 200-204 . - ISSN 0368-2781
Аннотация: A clinical study was performed on SY5555, a newly developed penem antibiotic, in children. SY5555 was given orally to 14 patients at 19'ЭКВИВ'29 mg/kg/day in 3 doses for 4 to 12 days. Clinical evaluations were made on the 14 patients including 4 with pharyngitis, 7 with tonsillitis, one with urinary tract infection, and 2 with impetigo. Overall clinical effects were excellent in 2, good in 12, with an efficacy rate of 100%. Causative organisms (Staphylococcus aureus and Streptococcus pyogenes) were all eradicated. As to adverse reactions, mild diarrhea was observed in 4 patients. These data suggest that SY5555 is a useful oral antibiotic for the treatment of bacterial infections in children. Библ. 5
ГРНТИ  
34.27.29
ВИНИТИ 341.27.29.25.07
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
ДОЗИРОВАНИЕ
АНТИБАКТЕРИАЛЬНОЕ ДЕЙСТВИЕ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
ЛЕЧЕНИЕ
БОЛЬНЫЕ ДЕТИ
МЛАДЕНЦЫ

Доп.точки доступа:
Higashino, Hirohiko; Kobayashi, Yohnosuke
15.
РЖ ВИНИТИ 76 (BI31) 95.11-04Т3.257

   
    Клиническое изучение SY 5555 при детских инфекциях [Text] / Kenji Niinou [et al.] // Jap. J. Antibiot. - 1995. - Vol. 48, N 1. - С. 49-70 . - ISSN 0368-2781
Аннотация: Pharmacokinetic and clinical studies of SY5555, a new oral penem antibiotics, were performed in pediatric infections and the following results were obtained. Pharmacokinetics studies. Pharmacokinetics of SY5555 was studied in 5 children (5y1m'ЭКВИВ'10y11m) using doses of 5 mg/kg and 10 mg/kg. The average peak plasma levels were 0.65 'мю'g/ml at 1 or 2 hours after administration of 5 mg/kg and 2.12 'мю'g/ml at 1 or 2 hours after administration of 10 mg/kg, and the plasma half-lives were 0.81 and 1.08 hours, respectively. Average cumulative urinary recovery rates at 0'ЭКВИВ'6 hours were 2.97 and 3.96%, respectively. Clinical studies. SY5555 was administered to 45 patient with various infectious diseases (2 with acute pharyngitis, 8 with acute tonsillitis, 4 with lacunar tonsillitis, 3 each with acute bronchitis, pneumonia and pertussis, 7 with scarlet fever, 3 with impetigo contagiosa, 6 with acute urinary tract infections, 2 with balanoposthitis and 1 each with cervical lymphadenitis, S.S.S.S., vulvitis and acute colitis) at daily doses between 3.4'ЭКВИВ'10 mg/kg, t.i.d., for 3'ЭКВИВ'14 days. Clinical responses were excellent in 27 patients, good in 15 patients, fair in 1 patient, and poor in 2 patients, and the efficacy rate was 93.3%. Causative organisms were examined and 39 strains of 11 species were identified. The eradication rate was 78.9%. Side effects were observed in 1 patient with diarrhea. An abnormal laboratory test value was observed in 1 patient with elevation of eosinophils. The above results suggest that SY5555 may be a very useful and safe drug for the treatment of pediatric infection
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.02
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
SY 5555
ФАРМАКОКИНЕТИКА
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Niinou, Kenji; Sigeta, Midori; Kuwahata, Keiko; Suzuki, Hiroyuki; Sato, Hajime
16.
РЖ ВИНИТИ 34 (BI39) 96.02-04К1.649

    Pallister, C. J.
    Phagocytic NADPH oxidase and its role in chronic granulomatous disease [Text] / C. J. Pallister, J. T. Hancock // Brit. J. Biomed. Sci. - 1995. - Vol. 52, N 2. - P149-156 . - ISSN 0967-4845
Перевод заглавия: Фагоцитарная НАДФоксидаза и ее роль при хронических гранулематозных заболеваниях
Аннотация: Chronic granulomatous disease is an inherited disease manifest as recurrent bacterial and fungal infections. Although extremely rare, in the absence of long-term treatment it can lead to death at an early age. Even though the disease was first described almost 40 years ago it is only recently that the enzymatic defects which cause the disease have been well characterised, allowing an instructive classification of the disorder and paving the way for advances in gene therapy as a lasting cure. Ил. 1. Табл. 1. Библ. 91
ГРНТИ  
34.43.59
ВИНИТИ 341.43.59.07
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
МИКОЗЫ
БОЛЕЗНЬ ГРАНУЛЕМАТОЗНАЯ ХРОНИЧЕСКАЯ
МАГРОФАГИ
НАДФОКСИДАЗА
ЧЕЛОВЕК

Доп.точки доступа:
Hancock, J.T.
17.
РЖ ВИНИТИ 76 (BI40) 96.02-04М7.124

    Pallister, C. J.
    Phagocytic NADPH oxidase and its role in chronic granulomatous disease [Text] / C. J. Pallister, J. T. Hancock // Brit. J. Biomed. Sci. - 1995. - Vol. 52, N 2. - P149-156 . - ISSN 0967-4845
Перевод заглавия: Фагоцитарная НАДФоксидаза и ее роль при хронических гранулематозных заболеваниях
Аннотация: Chronic granulomatous disease is an inherited disease manifest as recurrent bacterial and fungal infections. Although extremely rare, in the absence of long-term treatment it can lead to death at an early age. Even though the disease was first described almost 40 years ago it is only recently that the enzymatic defects which cause the disease have been well characterised, allowing an instructive classification of the disorder and paving the way for advances in gene therapy as a lasting cure. Ил. 1. Табл. 1. Библ. 91
ГРНТИ  
76.03.49
ВИНИТИ 761.03.49.25.23.99
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
МИКОЗЫ
БОЛЕЗНЬ ГРАНУЛЕМАТОЗНАЯ ХРОНИЧЕСКАЯ
МАГРОФАГИ
НАДФОКСИДАЗА
ЧЕЛОВЕК

Доп.точки доступа:
Hancock, J.T.
18.
РЖ ВИНИТИ 76 (BI31) 96.04-04Т3.384

   
    Фармакокинетические и клинические исследования цефозопрана в области педиатрии [Text] / Ryochi Fujii [et al.] // Jap. J. Antiobiot. - 1994. - Vol. 47, N 1. - С. 102-123 . - ISSN 0368-2781
Аннотация: Представлены результаты проведенных в 18 институтах фармакокинетических и клинических исследований нового цефемового антибиотика цефозопрана (ЦФ; SCE-2787) против различных инфекций у детей. Макс. конц-ии ЦФ в крови детей через 30 мин после в/в введения ЦФ (10, 20 и 40 мг/кг) составляли 21,7, 51,5 и 77,8 мкг/мл соотв. Величины Т[1/2] для ЦФ были равны 1,99, 1,85, и 1,67 ч соотв. Скорости экскреции ЦФ с мочой в первые 6 ч после введения составляли 87,3, 67,4 и 84,1% соотв. Конц-ии ЦФ в спинномозговой жидкости б-ных менингитом через 1-1,5 ч после введения ЦФ (50 мг/кг, в/в) находились в диапазоне конц-ий 1,6-43,4 мкг/мл. Сделан вывод о том, что ЦФ обладает оптимальными для парентерального цефемового антибиотика характеристиками и является высокоэффективным и безопасным средством. Япония, School of Med., Teikyo Univ. Библ. 10
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.33.05
Рубрики: НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
ЦЕФОЗОПРАН
ФАРМАКОКИНЕТИКА
СОДЕРЖАНИЕ В КРОВИ
СОДЕРЖАНИЕ В СПИННОМОЗГОВОЙ ЖИДКОСТИ
ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
БОЛЬНЫЕ ДЕТИ

Доп.точки доступа:
Fujii, Ryochi; Abe, Toshiaki; Tajima, Tsuyoshi; Terashima, Itaru; Meguro, Hidenori; Nakazawa, Susumu; Sato, Hajime
19.
РЖ ВИНИТИ 76 (BI31) 96.04-04Т3.405

   
    Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home [Text] / Jean-Luc Benoit [et al.] // Clin. Infec. Diseases. - 1995. - Vol. 21, N 5. - P1286-1288 . - ISSN 1058-4838
Перевод заглавия: Интралюминальное лечение антибиотиками инфекции при внутривенном введении катетера у больных, получающих парентеральное питание в домашних условиях
Аннотация: We carried out an open, uncontrolled, prospective study to evaluate intraluminal antibiotic therapy for bloodstream infections arising from subcutaneously tunneled central venous catheters in patients receiving parenteral nutrition therapy at home. Seven bacterial infections were treated with intraluminal antibiotics (mean duration, 8.6 days) sometimes accompanied by systemic antibiotics (mean duration, 2.1 days). All seven infections were cured. Two infections caused by Candida species were treated with intraluminal amphotericin B. Fungal infection was suppressed during treatment but later relapsed, as confirmed by pulsed field DNA electrophoresis typing of bloodstream isolates. The concentration of antibiotic was assayed in intraluminal fluid from catheters of patients receiving treatment with vancomycin or gentamicin. The concentration was initially 'ЭКВИВ'5 mg/mL, and it remained at '='2.5 mg/mL throughout the period that the solution was locked in the catheter. Our findings show that intraluminal therapy is effective against selected bacterial infections and can suppress fungal infections in subcutaneously tunneled catheters. США, Univ. of Chicago, Mc 5065, Chicago, Illinois 60637. Библ. 11
ГРНТИ  
76.31.29
ВИНИТИ 761.31.29.35.02
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
АНТИБИОТИКИ
ДОЗИРОВАНИЕ
ПАРЕНТЕРАЛЬНОЕ ПИТАНИЕ
БОЛЬНЫЕ

Доп.точки доступа:
Benoit, Jean-Luc; Carandang, Godofredo; Sitrin, Michael; Arnow, Paul M.
20.
РЖ ВИНИТИ 34 (BI14) 96.06-04Б4.291

   
    Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home [Text] / Jean-Luc Benoit [et al.] // Clin. Infec. Diseases. - 1995. - Vol. 21, N 5. - P1286-1288 . - ISSN 1058-4838
Перевод заглавия: Интралюминальное лечение антибиотиками инфекции при внутривенном введении катетера у больных, получающих парентеральное питание в домашних условиях
Аннотация: We carried out an open, uncontrolled, prospective study to evaluate intraluminal antibiotic therapy for bloodstream infections arising from subcutaneously tunneled central venous catheters in patients receiving parenteral nutrition therapy at home. Seven bacterial infections were treated with intraluminal antibiotics (mean duration, 8.6 days) sometimes accompanied by systemic antibiotics (mean duration, 2.1 days). All seven infections were cured. Two infections caused by Candida species were treated with intraluminal amphotericin B. Fungal infection was suppressed during treatment but later relapsed, as confirmed by pulsed field DNA electrophoresis typing of bloodstream isolates. The concentration of antibiotic was assayed in intraluminal fluid from catheters of patients receiving treatment with vancomycin or gentamicin. The concentration was initially 'ЭКВИВ'5 mg/mL, and it remained at '='2.5 mg/mL throughout the period that the solution was locked in the catheter. Our findings show that intraluminal therapy is effective against selected bacterial infections and can suppress fungal infections in subcutaneously tunneled catheters. США, Univ. of Chicago, Mc 5065, Chicago, Illinois 60637. Библ. 11
ГРНТИ  
34.27.29
ВИНИТИ 341.27.29.25.07
Рубрики: ИНФЕКЦИИ БАКТЕРИАЛЬНЫЕ
АНТИБИОТИКИ
ДОЗИРОВАНИЕ
ПАРЕНТЕРАЛЬНОЕ ПИТАНИЕ
БОЛЬНЫЕ

Доп.точки доступа:
Benoit, Jean-Luc; Carandang, Godofredo; Sitrin, Michael; Arnow, Paul M.
 1-20    21-40   41-60   61-80   81-100   101-120      
 
Описание базы
Стандартный
По словарю
Расширенный
Профессиональный
Распределенный
ГРНТИ



"Электронные каталоги и базы данных библиотек СО РАН"
© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)